Clinical Trials on MYC Amplification

Total 134 results

Vincerx Pharma, Inc.

Terminated

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Relapsed Non Hodgkin Lymphoma | Richter Syndrome | MYC Amplification | MYC Overexpression | MYC Translocation

United States, Poland
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

DLBCL | Untreated | MYC Gene Rearrangement

China
Assiut University

Not yet recruiting

LAMP Assay Versus PCR for Detection of blaNDM-1 and blaKPC Genes

Gene Amplification
Merrimack Pharmaceuticals

Completed

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

HER-2 Gene Amplification

United States
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
Jin-Hee Ahn
Asan Medical Center

Unknown

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor (BIOs-Her)

HER-2 Gene Amplification | HER-2 Protein Overexpression
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
Taiho Oncology, Inc.

Active, not recruiting

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer | FGFR2 Amplification | FGFR 1 High Amplification

Italy, United States, France, United Kingdom, Spain, Portugal, Canada
Kidney Cancer Research Bureau

Recruiting

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2)

Metastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene Amplification

United States
Arog Pharmaceuticals, Inc.

Available

Individual Patient Compassionate Use of Crenolanib

FLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene Amplification

Italy
Inonu University
Anadolu University

Active, not recruiting

Inflammatory and Anti-Inflammatory Gene Expressions in Liver Transplant Patients

Infections | Immune Response | Liver Transplant; Complications | Gene Amplification

Turkey
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
Chungbuk National University Hospital
Merck KGaA, Darmstadt, Germany

Recruiting

Tepotinib in Solid Tumors Harboring MET Alterations

Solid Tumor | MET Amplification | MET Exon 14 Skipping Mutation

Korea, Republic of
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Joseph Tuscano
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Carcinoma, Transitional Cell | HER-2 Gene Amplification

China
Cothera Bioscience, Inc

Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphatic Diseases | Burkitt Lymphoma | High-grade B-cell Lymphoma | C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma | C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma | Lymphoma, High-Grade | C-Myc Gene Rearrangement

Korea, Republic of, China
Symphogen A/S

Completed

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene Amplification

United States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain
ShiCang Yu
Xinqiao Hospital of Chongqing

Not yet recruiting

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

MSC

China
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
University Hospital, Brest

Unknown

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer (EPTTCSM)

Breast Neoplasms | HER-2 Gene Amplification

France
Sameek Roychowdhury
National Cancer Institute (NCI)

Withdrawn

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditions

United States
Tianjin Medical University Second Hospital

Recruiting

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Solid Tumor | FGF Receptor Gene Mutation | FGF Amplification | FGF Receptor Gene Family Rearrangement | FGF Receptor Gene Translocation

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements

United States
Texas Christian University

Completed

Family Assessment Motivation, and Linkage Intervention (FAMLI) (FAMLI)

Mapping Enhanced Counseling (MEC) | Active Linkage (AL)

United States
Chania General Hospital "St. George"
University of Thessaly

Not yet recruiting

The Effect of Listening Effort, Cognition and Anxiety-depression in Listening Satisfaction by Hearing Aid Users

Depression | Anxiety | Cognitive Function 1, Social | Satisfaction, Consumer | Amplification | Hearing Aid | Listening Effort
Instituto Nacional de Enfermedades Respiratorias

Completed

Morphofunctional Analysis and Gene Expression of Inflammation Molecules and Response Mechanisms to Oxidative Stress in Kidney Tissue of Deceased Patients With SARS-CoV-2 Virus Infection: "Ancestral Variant"

COVID-19 | Inflammatory Response | Oxidative Stress | Kidney Injury | Gene Amplification

Mexico
Lapo Alinari

Recruiting

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC... and other conditions

United States
Terumo BCT

Completed

An Evaluation of the Spectra Optia CMNC Collection Procedure (CMNC)

Healthy Apheresis Donors | Mononuclear (MNC) Cell Donors

United States
University of Colorado, Denver
Sonova AG

Recruiting

Assessing Speech Perception and Amplification Benefit During Infancy

Hearing Loss | Speech Perception | Children With Hearing Differences | Amplification

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditions

United States
University of Washington
National Institute of Mental Health (NIMH)

Completed

Brief Online Training (BOLT) for Routine Outcome Monitoring

Mental Health Issue | Adoption of Measurement-Based Care (MBC)

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

HER2 Expression / Amplification in Patients With Biliary Tract Cancer

China
Prelude Therapeutics

Completed

A Study of PRT2527 in Participants With Advanced Solid Tumors

Sarcoma | Non-small Cell Lung Cancer | Castrate Resistant Prostate Cancer | Solid Tumors With Known MYC Amplification | Hormone Receptor Positive HER2 Negative Breast Cancer

United States
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Samsung Medical Center

Completed

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Glioblastoma, Adult | EGFR Amplification

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
University of Chicago
Novartis

Terminated

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...

United States
Merrimack Pharmaceuticals

Terminated

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Stomach Cancer | Gastroesophageal Junction Cancer | HER-2 Gene Amplification | Esophagus Cancer

United States
Sun Yat-sen University
307 Hospital of PLA; Fudan University; West China Hospital; Tongji Hospital; Second... and other collaborators

Completed

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Stomach Neoplasms | ERBB2 Gene Amplification | Neoplasms Metastasis

China
Michael Wagner
Edgewood Oncology Inc.

Not yet recruiting

BTX-A51 in Patients With Liposarcoma

Liposarcoma | MDM2 Gene Amplification | Metastatic Liposarcoma | Unresectable Liposarcoma | Recurrent Liposarcoma

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
Changhoon Yoo

Completed

Trastuzumab in HER2-positive Biliary Tract Cancer (BILHER)

Cholangiocarcinoma | Biliary Tract Cancer | HER-2 Gene Amplification | HER-2 Protein Overexpression

Korea, Republic of
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
Xiaohua Zhu

Recruiting

PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer

NSCLC Stage IV | PD-L1 Gene Amplification

China
Haihe Biopharma Co., Ltd.

Unknown

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Negative T790M Mutation and Met Amplification

China

Clinical Trials on MYC Amplification

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations